-
Insilico Plans Pivotal Trial for AI-Based IPF Candidate
12 Nov 2024 15:15 GMT
… #47;Avalide® (irbesartan), and Letairis® (ambrisentan).
“With her leadership … of novel drugs, and revolutionize the treatment landscape by … Medical College and the Phase IIa trial’s principal investigator.
U.S. trial … in March in Nature Biotechnology, a team of …
-
Managing Pulmonary Arterial Hypertension: Diagnosis, Classification, and Treatment Strategies
30 Apr 2024 02:50 GMT
… Inc), ambrisentan (Letairis; Gilead), and macitentan (Opsumit; Actelion Pharmaceuticals Ltd). Drugs that target … going to drive your initial treatment decision.”
According to Smith, …
REFERENCE
Smith ZR. The Evolving Treatment Paradigm for the Management of …
-
Evolving Landscape of Cardiology Segment: Key Market Insights of Latest Published Rare Cardiovascular Diseases Report — Giant-Cell Arteritis, Pulmonary Arterial Hypertension, and Restrictive Cardiomyopathy | DelveInsight
14 Jan 2025 18:00 GMT
… current treatment practices, emerging drugs, market … Novartis Pharmaceuticals
Mavrilimumab: CSL/Kiniksa Pharmaceuticals
TREMFYA … sildenafil), ADCIRCA (tadalafil), LETAIRIS/VOLIBRIS (ambrisentan … Hypertension Clinical Trials Restrictive Cardiomyopathy …
-
Drug Name Confusion: List of Problem Medications Grows
08 Aug 2023 14:15 GMT
… Letairis (Ambrisentan) is a vasodilator for the treatment … of pulmonary arterial hypertension. Citalopram (Celexa) is an antidepressant … serious medication mistake when the wrong drug is … Industry."
FDA Center for Drug Evaluation and Research …
-
Ambrisentan Drug Market Covering Prime Factors and Competitive Outlook till 2027 |Top Countries data with COVID 19 Analysis| Top Key Players
10 May 2021 06:19 GMT
… Ambrisentan (U.S. trade name Letairis; E.U. trade name Volibris … ) is a drug indicated for use in the treatment of pulmonary hypertension … . Market Analysis and Insights: Global Ambrisentan Drug …
-
Gilead's Q1 Results Show Just How Much the Biotech Is Relying on Its COVID Drug
30 Apr 2021 10:09 GMT
… the market close. The biotech stock slid nearly 3% lower … to $220 million.
However, the biotech had plenty of problem areas … company's older products, Letairis and Ranexa, also experienced further … the biotech relying so heavily on the COVID-19 drug for …
-
Gilead to pay $97M to settle violations of False Claims Act related to Letairis copays
23 Sep 2020 21:33 GMT
… of Medicare beneficiaries using its pulmonary arterial hypertension (PAH) med Letairis … (ambrisentan).
Johnson & Johnson unit Actelion Pharmaceuticals settled similar … claims in 2018 related to its PAH drugs.
-
Gilead’s top-line slips 10% as demand for HIV/hepatitis C drugs drops
31 Jul 2020 13:19 GMT
… sales of its pulmonary hypertension drug Letairis (ambrisentan) and chest pain med … recent acquisition of immuno-oncology biotech Forty Seven.
Despite the decline … thanks to its investigational antiviral treatment remdesivir, which is currently being …
-
Gilead Rises As Drug Shows Effectiveness To Combat Coronavirus
04 Feb 2020 22:56 GMT
… a randomized, controlled trial to determine whether remdesivir … hope." Trials for the drug will be conducted … Letairis (pulmonary arterial hypertension) was a combined $152 million. These drugs … upside from a coronavirus treatment could overshadow any talk …
-
Cardiovascular Drugs Market to be worth US$ 91.0 Billion by 2025, Says TMR
20 Aug 2019 12:30 GMT
… through counselling and medicines as per their … for hypertension specific drugs such as Letairis, Tracleer, and … lost its hyperlipidemia treatment drug patent in early 2016 … FDA gave its approval to Watson Pharmaceuticals Inc. to launch a generic drug …
About
© 1995-2025